Trials & R&D · first seen 9h ago, updated 9h ago
Chronic Kidney Disease Market: 5 Emerging Therapies to Watch as the Treatment Landscape Expected to Evolve by 2036 | DelveInsight
A diversified late-stage pipeline encompassing endothelin receptor antagonists, aldosterone synthase inhibitors such as lorundrostat, APOL1 inhibitors including MZE829, and cell therapy approaches such as rilparencel is poised to intensify…
Summary from PR Newswire - Clinical Trials.